Wedbush Securities Inc. Sells 731 Shares of Edwards Lifesciences Corporation $EW

Wedbush Securities Inc. reduced its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 4.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,203 shares of the medical research company’s stock after selling 731 shares during the quarter. Wedbush Securities Inc.’s holdings in Edwards Lifesciences were worth $1,267,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nuveen LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $330,881,000. Jennison Associates LLC lifted its holdings in Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. Mirova US LLC boosted its position in Edwards Lifesciences by 56.2% in the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after buying an additional 1,054,301 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Edwards Lifesciences during the second quarter worth about $67,832,000. Finally, Woodline Partners LP grew its stake in Edwards Lifesciences by 7,805.0% during the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock worth $59,822,000 after buying an additional 814,917 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 1.1%

Shares of EW opened at $83.37 on Monday. The business’s fifty day moving average price is $77.78 and its two-hundred day moving average price is $77.41. The firm has a market capitalization of $48.38 billion, a price-to-earnings ratio of 12.00, a PEG ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 52 week low of $64.89 and a 52 week high of $87.09. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Piper Sandler reaffirmed an “overweight” rating and set a $95.00 price target (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Canaccord Genuity Group reiterated a “hold” rating and issued a $84.00 price objective (up previously from $81.00) on shares of Edwards Lifesciences in a research report on Monday, November 3rd. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Tuesday, July 29th. Finally, Truist Financial increased their target price on Edwards Lifesciences from $87.00 to $90.00 and gave the stock a “hold” rating in a report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $91.39.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.